Figure 1.

Responses to two different ALK plus MET combination regimens. Longitudinal axial computed tomography images reveal (A) baseline lung mass immediately before initiating lorlatinib plus crizotinib and (B) significant decrease in the lung mass on combination therapy. Longitudinal computed tomography coronal images reveal (C) baseline liver mass immediately before initiating alectinib plus capmatinib and (D) significant decrease in the size of the liver lesion as denoted by an asterisk on combination therapy. Treatment histories are presented above the images for each patient. Bev, bevacizumab.